DESCRIPTION (Adapted from applicant's abstract):
Atypical PKC isoforms (iota/zeta) have been shown to play a critical role in
regulation of various neuronal processes including, differentiation, survival
and long-term potentiation. In PC-12 cells a PKCs, as well as their second
messenger activator, P13 polyphosphoinositides, are required for both
differentiation and survival responses. We have recently shown that aPKCs are
tyrosine phosphorylated in response to nerve growth factor (NGF). ZIP/p62 and
Par4 are binding proteins that regulate the localization and activation of
aPKCs. Preliminary studies document an NGF receptor-regulated phosphotyrosine
dependent interaction of src with sPKC. We hypothesize that tyrosine
phosphorylation of atypical PKC by src moduates activity, as well as, its
ability to interact with its protein regulators, Par4 and ZIP. Therefore, one
specific aim is to study the mechanisms by which aPKC-iota is regulated by
tyrosine phsophorylation to include regulation by NGF receptor components, p75
and TrkA, as well as, second messenger. A second aim is to unravel the
mechanismwhereby aPKC is regulated by src kinase to include regulation of aPKC
localization, signal-complex formation and interaction with protein regulators,
as well as to examine the specific tyrosine residues that regulate NGF/aPKC
signal-coupling. Various biochemical and functional assays will be used to
define the function of src in regulation of aPKC signaling. Overall, a
comprehensive set of experiments using enzyme activity assays, subcellular
fractionation, coimmunoprecipitation and site-directed mutagenesis will be
employed. The outcome of this work will continue to alter the conceptual
framework of neurotrophic signal coupling and the role that aPKC plays in this
process. These findings will contribute to further understanding of the
mechanism whereby aPKC is regulated and may provide new therapeutic targets for
neurodegenerative disorders.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
066470972
UEI
DMQNDJDHTDG4
Project Start Date
01-August-1995
Project End Date
31-July-2003
Budget Start Date
01-August-2001
Budget End Date
31-July-2003
Project Funding Information for 2001
Total Funding
$50,000
Direct Costs
$50,000
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2001
National Institute of Neurological Disorders and Stroke
$50,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3R01NS033661-06S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3R01NS033661-06S1
Patents
No Patents information available for 3R01NS033661-06S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3R01NS033661-06S1
Clinical Studies
No Clinical Studies information available for 3R01NS033661-06S1
News and More
Related News Releases
No news release information available for 3R01NS033661-06S1
History
No Historical information available for 3R01NS033661-06S1
Similar Projects
No Similar Projects information available for 3R01NS033661-06S1